

Date: February 12, 2026

To,
Listing Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Subject: Newspaper Advertisement for Unaudited Standalone Financial Results for the third quarter & nine months ended December 31, 2025.

Dear Sir/Madam,

Pursuant to Regulation 47(1) read with Schedule III of the SEBI (LODR) Regulations, 2015, please find enclosed a copy of newspaper advertisement dated February 12, 2026 for the extract of Unaudited Standalone financial results of the Company for the third quarter/nine months ended December 31, 2025 published in

1. 'Business Standard' (English) and
2. 'Dainik Nalanda Express; (Marathi)

The above publication is also available on the website of the company at www.aspiradiagnostics.com

Kindly take this intimation on your record.


Thanking you.


Yours Sincerely,
For **Aspira Pathlab & Diagnostics Limited**




Krupali Shah
Company Secretary & Compliance Officer

| LOTUS EYE HOSPITAL AND INSTITUTE LIMITED | | | | | | |
|--|--|------------------|------------|------------|-------------------|------------|
| CIN:L85110TZ1997PLC007783 | | | | | | |
| REGISTERED OFFICE: 770/12, AVINASHI ROAD, AERODROME POST, COIMBATORE 641 014 | | | | | | |
| PHONE NO.: 0422-4229900, 4229999, FAX: 0422-2627193, | | | | | | |
| E-MAIL: companysecretary@lotuseye.org, WEBSITE: www.lotuseye.org | | | | | | |
| EXTRACTS OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31 ,2025 | | | | | | |
| (Rs. In Lakhs) | | | | | | |
| Sl. No. | Particulars | Quarter ended on | | | Nine months ended | |
| | | 31-12-2025 | 30-09-2025 | 31-12-2024 | 31-12-2025 | 31-12-2024 |
| | | (Un-audited) | | | (Un-audited) | |
| | | | | | | 31-03-2025 |
| | | | | | | (Audited) |
| 1 | Total income for the period | 1,378.51 | 1,330.93 | 1,246.77 | 4,079.89 | 3,884.14 |
| 2 | Net Profit / (Loss) for the period before tax (before Exceptional items) | (37.56) | 7.24 | (42.35) | 42.39 | 54.07 |
| 3 | Net Profit / (Loss) for the period before tax (after Exceptional items) | (37.51) | 7.30 | (42.58) | 42.77 | 54.05 |
| 4 | Net Profit / (Loss) for the period after tax (after Exceptional items) | (26.07) | 11.58 | (23.91) | 39.99 | 48.69 |
| 5 | Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | (28.24) | 9.42 | (25.35) | 33.49 | 44.36 |
| 6 | Equity Share Capital | 2,079.63 | 2,079.63 | 2,079.63 | 2,079.63 | 2,079.63 |
| 7 | Earnings Per Share (of Rs.10/- each) | | | | | |
| | Basic (In Rs.): | (0.13) | 0.06 | (0.11) | 0.19 | 0.23 |
| | Diluted (In Rs.): | (0.13) | 0.06 | (0.11) | 0.19 | 0.23 |
| Notes: | | | | | | |
| 1 The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 11, 2026. The above results has also been subjected to limited review by statutory auditors of the company. | | | | | | |
| 2 The above is an extract of the detailed format of Quarterly Financial Results filed with Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the financial results for the Quarter ended December 31, 2025 is available on the Stock Exchange websites, www.bseindia.com/www.nseindia.com and the Company's website www.lotuseye.org. | | | | | | |
| For and on behalf of Board of Directors | | | | | | |
| LOTUS EYE HOSPITAL AND INSTITUTE LIMITED | | | | | | |
| Sd/- | | | | | | |
| Ms. Sangeetha Sundaramoorthy | | | | | | |
| Managing Director | | | | | | |
| Place : Coimbatore | | | | | | |
| Date : February 11, 2026. | | | | | | |

| KRYPTON INDUSTRIES LTD. | | | | | | | | | |
|---|------------------------------|------------------------------|--------------------------|--------------------------|------------------------------|------------------------------|--------------------------|--------------------------|--|
| CIN: L25199WB1990PLC048791 | | | | | | | | | |
| Regd. Office : Banganagar, Diamond Harbour Road, Falta, Fatehpur (South 24 Parganas), West Bengal - 743 513, India | | | | | | | | | |
| Head Office : 410, Vardaan Building, 25A, Camac Street, Kolkata - 700 016, Email id: krypton@kryptongroup.com | | | | | | | | | |
| EXTRACTS OF THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025 | | | | | | | | | |
| (₹ in Lakhs) | | | | | | | | | |
| PARTICULARS | STANDALONE | | | | CONSOLIDATED | | | | |
| | NINE MONTHS ENDED 31.12.2025 | NINE MONTHS ENDED 31.12.2024 | Quarter Ended 31.12.2025 | Quarter Ended 31.12.2024 | NINE MONTHS ENDED 31.12.2025 | NINE MONTHS ENDED 31.12.2024 | Quarter Ended 31.12.2025 | Quarter Ended 31.12.2024 | |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |
| 1 Total Income from Operations (net) | 3,562.47 | 3,292.77 | 1,265.75 | 1,078.60 | 3,562.47 | 3,391.69 | 1,265.75 | 1,100.89 | |
| 2 Net Profit / (Loss) for the period (before Tax, Exceptional and Extraordinary items #) | 247.69 | 158.98 | 92.32 | 33.26 | 247.54 | 134.00 | 92.31 | 17.17 | |
| 3 Net Profit / (Loss) for the period before Tax (after Exceptional and Extraordinary items #) | 246.29 | 158.98 | 90.92 | 22.26 | 246.14 | 147.50 | 90.91 | 30.67 | |
| 4 Net Profit / (Loss) for the period after Tax (after Exceptional and Extraordinary items #) | 186.29 | 116.98 | 70.92 | 22.26 | 186.14 | 105.50 | 70.91 | 19.67 | |
| 5 Total Comprehensive Income for the period [Comprising (Profit)/ (Loss) for the period (after tax) and other Comprehensive Income (after Tax)] | 186.29 | 116.98 | 70.92 | 22.26 | 186.14 | 105.50 | 70.91 | 19.67 | |
| 6 Equity Share Capital | 1,469.71 | 1,469.71 | 1,469.71 | 1,469.71 | 1,469.71 | 1,469.71 | 1,469.71 | 1,469.71 | |
| 7 Reserves excluding Revaluation Reserve as shown in the Balance Sheet on previous accounting year | - | - | - | - | - | - | - | - | |
| 8 Earnings per Share (for continuing and discontinued operations) (Face Value of ₹10/- each) | | | | | | | | | |
| Basic & Diluted (*Not Annualised) | 1.27 | 0.80 | 0.48 | 0.15 | 1.27 | 0.73 | 0.48 | 0.13 | |
| Note: | | | | | | | | | |
| a) The above is an extract of the detailed format of Quarter and Nine Months ended 31st December 2025 Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly Financial Results are available on Stock Exchange Websites (www.bseindia.com) and on the Company's Website (www.kryptongroup.com). The same can also be accessed by scanning QR Code provided below: | | | | | | | | | |
|  | | | | | | | | | |
| Place : Kolkata | | | | | | | | | |
| Date : 11.02.2026 | | | | | | | | | |
| for & on behalf of the Board | | | | | | | | | |
| Priya Agarwal | | | | | | | | | |
| Company Secretary & Compliance Officer | | | | | | | | | |

| HINDUJA GLOBAL SOLUTIONS LIMITED | | | | | | | |
|---|--|---------------------------|---------------------------|---|--|---|--------------------------------|
| (CIN: L92199MH1995PLC084610) | | | | | | | |
| Regd. Office : Tower C (1 st floor), Plot C-21, G Block, Bandra Kurla Complex, Bandra East, Mumbai - 400 051. | | | | | | | |
| Contact no.: 022 - 6136 0407; Website: www.hgs.cx; E-mail: investor.relations@teamhgs.com | | | | | | | |
| EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025 | | | | | | | |
| (₹ in Crores) | | | | | | | |
| S. No. | Particulars (Refer Notes Below) | 3 months ended 31.12.2025 | 3 months ended 30.09.2025 | Corresponding 3 months ended 31.12.2024 | Year to date figures for Current period ended 31.12.2025 | Year to date figures for Previous period ended 31.12.2024 | Previous year ended 31.03.2025 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| | | (i) | (ii) | (iii) | (iv) | (v) | (vi) |
| 1 | Total income from operations (both continuing and discontinued operations) | 1,272.58 | 1,222.94 | 1,234.87 | 3,750.41 | 4,036.46 | 5,334.18 |
| 2 | Net Profit / (Loss) for the period/ year before tax (after Exceptional items) | 39.35 | (14.09) | 41.26 | 66.42 | 174.93 | 278.38 |
| 3 | Net Profit / (Loss) for the period/ year after tax (after Exceptional items) | 34.35 | (26.99) | (8.59) | 18.52 | 102.41 | 100.72 |
| 4 | Total Comprehensive Income for the period/ year [Comprising Profit / (Loss) for the period/ year (after tax) and Other Comprehensive Income (after tax)] | 109.48 | 116.78 | 4.65 | 351.15 | 208.05 | 232.05 |
| 5 | Equity Share Capital | 46.52 | 46.52 | 46.52 | 46.52 | 46.52 | 46.52 |
| 6 | Reserves excluding Revaluation Reserve as per Balance Sheet | | | | | | 7,661.60 |
| 7 | Earnings Per Share for the period/ year (of ₹ 10/- each) (both continuing and discontinued operations) | | | | | | |
| | - Basic EPS (for the period - not annualised) | 9.15 | (4.20) | (0.57) | 8.70 | 25.28 | 26.10 |
| | - Diluted EPS (for the period - not annualised) | 9.15 | (4.20) | (0.57) | 8.70 | 25.28 | 26.10 |
| Notes: | | | | | | | |
| 1. The above is an extract of the detailed format of the Consolidated Financial Results for the Quarter ended and Nine months ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid Financial Results are available on the Stock Exchange websites; www.nseindia.com and www.bseindia.com and Company's website https://hgs.com/wp-content/uploads/2026/02/HGSLOUTCOMEBSM-s.pdf. The same can also be accessed by scanning below QR code | | | | | | | |
|  | | | | | | | |
| For Hinduja Global Solutions Limited | | | | | | | |
| Pradeep Udhas | | | | | | | |
| Independent Director | | | | | | | |
| DIN: 02207112 | | | | | | | |
| Place : Mumbai | | | | | | | |
| Date : February 10, 2026 | | | | | | | |

| Dvara Kshetriya Gramin Financial Services Private Limited | | | | | | |
|--|---|------------------|-------------------|------------------------|-------------------|------------------------|
| CIN: U65991TN1993PTC024547 | | | | | | |
| Regd. Office: IITM Research Park, Phase I, 10th Floor, Kanagam Village, Taramani, Chennai - 600 113 | | | | | | |
| Statement of Unaudited Financial Results for the Quarter and Nine months ended 31 December 2025 | | | | | | |
| (All amounts are in Indian Rupees in Lakhs, except share data and as stated) | | | | | | |
| Sl. No. | Particulars | Quarter ended | | | Nine Months ended | |
| | | 31 December 2025 | 30 September 2025 | 31 December 2024 | 31 December 2025 | 31 December 2024 |
| | | Unaudited | Unaudited | (Unaudited & Restated) | Unaudited | (Unaudited & Restated) |
| 1 | Total income from operations | 13,147.79 | 14,721.62 | 16,171.89 | 40,224.75 | 46,805.84 |
| 2 | Net profit for the year (before tax, exceptional and/or extraordinary items) | 130.01 | 1,032.50 | (1,165.07) | (2,883.79) | 3,522.29 |
| 3 | Net profit for the year before tax (after exceptional and/or extraordinary items) | 130.01 | 1,032.50 | (1,165.07) | (2,883.79) | 3,522.29 |
| 4 | Net profit for the year after tax (after exceptional and/or extraordinary items) | 446.76 | 826.77 | (745.62) | (1,665.22) | 2,612.53 |
| 5 | Total comprehensive income for the year | 267.05 | (22.57) | (735.65) | (2,935.89) | 2,540.79 |
| 6 | Paid up equity share capital | 11,666.48 | 11,666.48 | 11,666.48 | 11,666.48 | 11,666.48 |
| 7 | Securities premium | 38,310.44 | 38,310.44 | 38,310.44 | 38,310.44 | 38,310.44 |
| 8 | Reserves (excluding capital reserve) | 26,536.24 | 26,249.67 | 28,332.44 | 26,536.24 | 28,332.44 |
| 9 | Net worth (Equity Share Capital + Other Equity + Compulsory Convertible Preference Shares ("CCPS")) | 42,160.16 | 41,873.59 | 39,998.92 | 42,160.16 | 39,998.92 |
| 10 | Paid up debt capital / outstanding debt securities (excluding CCPS) | 1,59,597.79 | 1,65,605.80 | 1,83,152.53 | 1,59,597.79 | 1,83,152.53 |
| 11 | Debt equity ratio (refer note d) | 3.79 | 3.95 | 4.58 | 3.79 | 4.58 |
| 12 | Earnings per share (of Rs. 100 each) | | | | | |
| | - Basic | 3.83 | 7.09 | (6.39) | (14.27) | 22.39 |
| | - Diluted | 3.83 | 7.09 | (6.40) | (14.27) | 22.37 |
| 13 | Capital redemption reserve | - | - | - | - | - |
| 14 | Debtenture redemption reserve (Refer note e) | NA | NA | NA | NA | NA |
| 15 | Debt service coverage ratio (Refer note f) | NA | NA | NA | NA | NA |
| 16 | Interest service coverage ratio (Refer note f) | NA | NA | NA | NA | NA |
| Notes: | | | | | | |
| a. The Sl. Nos. 1 to 8 are extracts from the detailed format of the statement of unaudited financial results for the quarter and nine months ended December 31, 2025, filed with the stock exchange under Regulation 52 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, as amended. The full format of the statement of unaudited financial results for the quarter and nine months ended December 31, 2025, is available on the website of the stock exchange ("https://www.bseindia.com/") and the Company ("https://www.dvarakfs.com/"). | | | | | | |
| b. The statement of unaudited financial results for the quarter and nine months ended December 31, 2025, has been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 10, 2026 & February 11, 2026. These unaudited financial results have been subjected to limited review by the statutory auditors of the Company, and the auditors have issued an unmodified review conclusion on the results. | | | | | | |
| c. These statements of unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in accordance with the Indian Accounting Standards ("Ind AS") as prescribed by the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Rules, 2016, notified under Section 133 of the Companies Act, 2013 ("The Act"), and other accounting principles generally accepted in India and in compliance with Regulation 52 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015. | | | | | | |
| d. Debt equity ratio = (Borrowings + Debt Securities + Subordinated Liabilities excluding CCPS) / Net Worth). | | | | | | |
| e. Debtenture redemption reserve is not required in respect of privately placed debtentures in terms of Rule 18(7)(b)(ii) of the Companies (Share Capital and Debtenture) Rules 2014. | | | | | | |
| f. The company is registered under the Reserve Bank of India Act 1934 as a Non-Banking Finance Company (NBFC), and generally, these ratios do not apply to it. Accordingly, no disclosure has been made. | | | | | | |
| g. The figures for the quarter ended December 31, 2025 and December 31, 2024, are the balancing figures between reviewed figures in respect of the nine months ended December 31, 2025 and December 31, 2024 and the reviewed figures for the half year ended September 30, 2025 and September 30, 2024, respectively. | | | | | | |
| For Dvara Kshetriya Gramin Financial Services Private Limited | | | | | | |
| LVLN Murty | | | | | | |
| Managing Director & CEO | | | | | | |
| DIN : 09618861 | | | | | | |
| Place : Chennai | | | | | | |
| Date : 11 th February 2026 | | | | | | |



ASPIRA PATHLAB & DIAGNOSTICS LIMITED

CIN: - L85100MH1973PLC289209

Reg. Office: Flat No.2, R.D. Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W.), Mumbai -400086

Corporate Off: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W),

Mumbai-40008. **Email ID:** info@aspiradiagnostics.com. **Website:** www.aspiradiagnostics.com

Extract of Unaudited Standalone Financial Results for the quarter & nine months ended December 31, 2025


(Rupees in Lakhs)

| Sr No | Particulars | Quarter Ended | | | Nine Month Ended | | Year Ended |
|-------|---|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
| | | 31.12.2025 (Unaudited) | 30.09.2025 (Unaudited) | 31.12.2024 (Unaudited) | 31.12.2025 (Unaudited) | 31.12.2024 (Unaudited) | 31.03.2025 (Audited) |
| 1. | Revenue from operations | 511.88 | 809.28 | 540.74 | 1,845.96 | 1,622.23 | 2199.90 |
| 2. | Net Profit / (Loss) for the period (before Tax, Exceptional and /or Extraordinary items) | (156.12) | 183.54 | 37.66 | 74.03 | 135.02 | 207.26 |
| 3. | Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items) | (156.12) | 183.54 | 37.66 | 74.03 | 135.02 | 207.26 |
| 4. | Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items) | (156.12) | 183.54 | 37.66 | 74.03 | 135.02 | 207.26 |
| 5. | Total Comprehensive Income for the period (Comprising profit/(loss) for the period (after tax) and other Comprehensive Income (after tax) | (156.12) | 183.54 | 37.66 | 74.03 | 135.02 | 207.30 |
| 6. | Equity Share Capital | 1029.30 | 1029.30 | 1029.30 | 1029.30 | 1029.30 | 1029.30 |
| 7. | Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year) | - | - | - | - | - | 192.34 |
| 8. | Earnings Per Share (of ₹10/- each) | | | | | | |
| | Basic: | (1.52) | 1.78 | 0.37 | 0.72 | 1.31 | 2.01 |
| | Diluted: | (1.52) | 1.78 | 0.37 | 0.72 | 1.31 | 2.01 |

Notes:

a. The above is an extract of the detailed format of Unaudited Standalone Financial Results for the Quarter/ Nine Month ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter/ Nine Month ended December 31, 2025 is available on the website of the BSE Limited and also on the Company's website:- www.aspiradiagnostics.com.

b. The above results have been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on February 10, 2026.



**For and on behalf of the Board
For Aspira Pathlab & Diagnostics Limited**

Sd/-

Nikunj Mange

Executive Director

DIN: 08489442

Place:- Mumbai

Date:- February 10, 2026

